Genfit (GNFT) Stock Forecast, Price Target & Predictions
GNFT Stock Forecast
Genfit stock forecast is as follows: an average price target of $13.00 (represents a 125.69% upside from GNFT’s last price of $5.76) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
GNFT Price Target
The average price target for Genfit (GNFT) is $13.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $13.00. This represents a potential 125.69% upside from GNFT's last price of $5.76.
GNFT Analyst Ratings
According to 1 Wall Street analysts, Genfit's rating consensus is 'Buy'. The analyst rating breakdown for GNFT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Genfit Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Ed Arce | H.C. Wainwright | $13.00 | $5.03 | 158.45% | 125.69% |
The latest Genfit stock forecast, released on Sep 23, 2024 by Ed Arce from H.C. Wainwright, set a price target of $13.00, which represents a 158.45% increase from the stock price at the time of the forecast ($5.03), and a 125.69% increase from GNFT last price ($5.76).
Genfit Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $13.00 | $13.00 |
| Last Closing Price | $5.76 | $5.76 | $5.76 |
| Upside/Downside | -100.00% | 125.69% | 125.69% |
In the current month, the average price target of Genfit stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Genfit's last price of $5.76. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 23, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Genfit's last stock rating was published by H.C. Wainwright on Sep 23, 2024. The company gave GNFT a "Buy" rating, the same as its previous rate.
Genfit Financial Forecast
Genfit Revenue Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | $29.94M | $48.05M | $76.76M |
| High Forecast | $29.94M | $48.05M | $76.76M |
| Low Forecast | $29.94M | $48.05M | $76.76M |
| # Analysts | 1 | 1 | 1 |
| Surprise % | - | - | - |
Genfit's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. GNFT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Genfit EBITDA Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| EBITDA | - | - | - |
| Avg Forecast | $-17.14M | $-27.50M | $-43.94M |
| High Forecast | $-17.14M | $-27.50M | $-43.94M |
| Low Forecast | $-17.14M | $-27.50M | $-43.94M |
| Surprise % | - | - | - |
undefined analysts predict GNFT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Genfit's previous annual EBITDA (undefined) of $NaN.
Genfit Net Income Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| Net Income | - | - | - |
| Avg Forecast | $84.85M | $18.96M | $46.79M |
| High Forecast | $84.85M | $18.96M | $46.79M |
| Low Forecast | $84.85M | $18.96M | $46.79M |
| Surprise % | - | - | - |
Genfit's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GNFT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Genfit SG&A Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| SG&A | - | - | - |
| Avg Forecast | $215.85M | $346.36M | $553.31M |
| High Forecast | $215.85M | $346.36M | $553.31M |
| Low Forecast | $215.85M | $346.36M | $553.31M |
| Surprise % | - | - | - |
Genfit's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to GNFT last annual SG&A of $NaN (undefined).
Genfit EPS Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| EPS | - | - | - |
| Avg Forecast | $1.41 | $0.31 | $0.78 |
| High Forecast | $1.41 | $0.31 | $0.78 |
| Low Forecast | $1.41 | $0.31 | $0.78 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, Genfit's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GNFT previous annual EPS of $NaN (undefined).
Genfit Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics | $1.08 | $8.75 | 710.19% | Buy |
| MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
| AVTE | Aerovate Therapeutics | $2.72 | $13.00 | 377.94% | Hold |
| FENC | Fennec Pharmaceuticals | $4.65 | $15.75 | 238.71% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
| ACRV | Acrivon Therapeutics | $7.85 | $22.00 | 180.25% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| RZLT | Rezolute | $5.44 | $13.50 | 148.16% | Buy |
| GNFT | Genfit | $5.76 | $13.00 | 125.69% | Buy |
| KROS | Keros Therapeutics | $59.95 | $102.00 | 70.14% | Buy |
| ADAG | Adagene | $3.05 | $5.00 | 63.93% | Buy |
| HRMY | Harmony Biosciences | $33.05 | $48.86 | 47.84% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| JANX | Janux Therapeutics | $55.87 | $61.20 | 9.54% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
GNFT Forecast FAQ
Is Genfit a good buy?
Yes, according to 1 Wall Street analysts, Genfit (GNFT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of GNFT's total ratings.
What is GNFT's price target?
Genfit (GNFT) average price target is $13 with a range of $13 to $13, implying a 125.69% from its last price of $5.76. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Genfit stock go up soon?
According to Wall Street analysts' prediction for GNFT stock, the company can go up by 125.69% (from the last price of $5.76 to the average price target of $13), up by 125.69% based on the highest stock price target, and up by 125.69% based on the lowest stock price target.
Can Genfit stock reach $9?
GNFT's average twelve months analyst stock price target of $13 supports the claim that Genfit can reach $9 in the near future.
What are Genfit's analysts' financial forecasts?
GNFT's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $76.76M (high $76.76M, low $76.76M), average EBITDA is $-43.935M (high $-43.935M, low $-43.935M), average net income is $46.79M (high $46.79M, low $46.79M), average SG&A $553.31M (high $553.31M, low $553.31M), and average EPS is $0.775 (high $0.775, low $0.775).